>
Noxopharm logo

NOX - Noxopharm Share Price

A$0.485 -0.1  -11.0%

Last Trade - 7:10am

Sector
Healthcare
Size
Small Cap
Market Cap £77.6m
Enterprise Value £67.3m
Revenue £3.26m
Position in Universe 752nd / 1907
Bullish
Bearish
Unlock NOX Revenue
Momentum
Relative Strength (%)
1m -16.0%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -44.9%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Jun 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.000 0.19 0.98 3.94 8.34 +1,134%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 31 December 2020, NoxopharmLtd revenues decreased 65% to A$1.3M. Net loss decreased 3%to A$6.7M. Revenues reflect Interest income decrease fromA$7K to A$0K. Lower net loss reflects CorporateAdministration Expenses decrease of 70% to A$756K (expense), Finance costs decrease of 49% to A$853K (expense),Research and Development Expenses decrease of 14% to A$3M(expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

NOX Revenue Unlock NOX Revenue

Net Income

NOX Net Income Unlock NOX Revenue

Normalised EPS

NOX Normalised EPS Unlock NOX Revenue

PE Ratio Range

NOX PE Ratio Range Unlock NOX Revenue

Dividend Yield Range

NOX Dividend Yield Range Unlock NOX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
NOX EPS Forecasts Unlock NOX Revenue
Profile Summary

Noxopharm Limited is a drug development company. The Company is engaged in the research and development of NOX66 in the field of adjuvant therapy in chemotherapy and radiotherapy. The Company focuses on developing a drug to treat cancer. The Company has a primary focus on the development of drugs to treat the problem of drug- and radio-resistance in cancer cells. The Company's drug NOX66 is a dosage formulation developed to protect idronoxil from being inactivated in the human body by Phase II metabolism. Its purpose is to ensure that idronoxil administered remains in an active form. The Company has its offices in Melbourne and Sydney.

Directors
Last Annual June 30th, 2020
Last Interim December 31st, 2020
Incorporated October 27, 2015
Public Since August 9, 2016
No. of Shareholders: 2,728
No. of Employees: n/a
Sector Healthcare
Industry Pharmaceuticals
Index
Exchange Australian Stock Exchange - SEATS
Shares in Issue 256,490,836
Free Float (0.0%)
Eligible for
ISAs
SIPPs
NOX Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for NOX
Upcoming Events for NOX
Frequently Asked Questions for Noxopharm
What is the Noxopharm share price?

As of 7:10am, shares in Noxopharm are trading at A$0.485, giving the company a market capitalisation of £77.6m. This share price information is delayed by 15 minutes.

How has the Noxopharm share price performed this year?

Shares in Noxopharm are currently trading at A$0.485 and the price has moved by 0.216k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Noxopharm price has moved by 0.136k% over the past year.

What are the analyst and broker recommendations for Noxopharm?

Of the analysts with advisory recommendations for Noxopharm, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Noxopharm is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Noxopharm next release its financial results?

Noxopharm is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Noxopharm dividend yield?

Noxopharm does not currently pay a dividend.

Does Noxopharm pay a dividend?

Noxopharm does not currently pay a dividend.

When does Noxopharm next pay dividends?

Noxopharm does not currently pay a dividend.

How do I buy Noxopharm shares?

To buy shares in Noxopharm you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Noxopharm?

Shares in Noxopharm are currently trading at A$0.485, giving the company a market capitalisation of £77.6m.

Where are Noxopharm shares listed? Where are Noxopharm shares listed?

Here are the trading details for Noxopharm:

Country of listing: Australia
Exchange: ASX
Ticker Symbol: NOX
What kind of share is Noxopharm?

Based on an overall assessment of its quality, value and momentum, Noxopharm is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Noxopharm share price forecast 2021?

We were not able to load any forecast data for Noxopharm.

How can I tell whether the Noxopharm share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Noxopharm. Over the past six months, the relative strength of its shares against the market has been -5.09%. At the current price of A$0.485, shares in Noxopharm are trading at 2.9% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Noxopharm PE Ratio?

The Noxopharm PE ratio based on its reported earnings over the past 12 months is 32.12. The shares are currently trading at A$0.485.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Noxopharm?

Noxopharm's management team is headed by:

Graham Kelly - CEO
Peter Marks - NVC
David Franks - SEC
Jeanette Bell - COO
Shawn Van Boheemen - CFO
Alexander Hunter - OTH
Boris Patkin - NED
Frederick Bart - NEC
Who are the major shareholders of Noxopharm?

Here are the top five shareholders of Noxopharm based on the size of their shareholding:

Kelly (Graham Edmund) Individual Investor
Percentage owned: 12.97% (36.2m shares)
Goodridge (Eleanore) Individual Investor
Percentage owned: 3.49% (9.73m shares)
Link Traders (Aust) Pty. Ltd. Corporation
Percentage owned: 2.41% (6.73m shares)
RGT Capital Fund No. 5 (Noxo) Pty. Ltd. Corporation
Percentage owned: 2.33% (6.50m shares)
Rhlc Pty. Ltd. Corporation
Percentage owned: 1.15% (3.22m shares)
Similar to NOX
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.